What is the purpose of this trial?
This study is designed to evaluate the safety and pharmacokinetics of BTCT4465A when administered as a single agent by intravenous (IV) infusion to participants with relapsed or refractory B-cell NHL and CLL. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Start Date: 05/03/2016
End Date: 10/31/2020
Last Updated: 10/09/2018
Study HIC#: 1509016491